---
mi_id: MIPR-node_8e23d05
type: press_release
canonical_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/more-results-less-money-each-chemistry-price-is-a-document/"
md_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/more-results-less-money-each-chemistry-price-is-a-document.md"

schema:
  "@type": NewsArticle
  "@id": MIPR-node_8e23d05
  url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/more-results-less-money-each-chemistry-price-is-a-document/"
  title: "More Results, Less Money Each — 5.13 Per Cent More Tests a Year, 10.26 Per Cent Less Revenue for Each, and the Cause Is a Fee Schedule"
  description: "USD 16.8bn (2025) to USD 22.5bn (2033) at 3.71%. Volume +5.13%, revenue per result -10.26%. A 16% US chemistry cut under a 15% cap, a 70% Jiangxi award, and 51.1% of the market unlisted."
  datePublished: "2026-11-15T13:09:55+00:00"
  dateModified: "2026-11-15T13:10:02+00:00"
  keywords:
    - clinical chemistry market
    - urinalysis market
    - clinical laboratory fee schedule
    - PAMA 2027
    - volume-based procurement
    - chemistry reagents
    - urine albumin creatinine ratio
    - KDIGO 2024
    - IVD market forecast
  isPartOf:
    - id: MISG-node_7e576db
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/diagnostics/"
      name: Diagnostics
    - id: MIIN-node_50b4dbf
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/"
      name: Healthcare
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research

acf:
  phoenix_meta_title: "More Results, Less Money Each: Chemistry Price Falls 10.26 Per Cent"
  phoenix_meta_description: "USD 16.8bn (2025) to USD 22.5bn (2033) at 3.71%. Volume +5.13%, revenue per result -10.26%. A 16% US chemistry cut under a 15% cap, a 70% Jiangxi award, and 51.1% of the market unlisted."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIPR-node_8e23d05
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIPR-node_8e23d05"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# More Results, Less Money Each — 5.13 Per Cent More Tests a Year, 10.26 Per Cent Less Revenue for Each, and the Cause Is a Fee Schedule

Pheonix Research has published *Global Clinical Chemistry and Urinalysis Market Report, Size, Share and Forecast 2026-2033: More Results, Less Money Each*, which sizes the discipline at **USD 16,800 million in 2025**, reaching **USD 22,490 million by 2033** at a compound annual rate of **3.71 per cent** — **1.339 times** and **USD 5,690 million** of absolute growth, carried on reportable results rising from **21,540 million to 32,130 million** at 5.13 per cent. The full report is available at [pheonixresearch.com](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-clinical-chemistry-and-urinalysis-market/).

The finding is that this is the only discipline in in vitro diagnostics whose price is published, and that both of the world’s price-setting mechanisms move downward inside the same eight-year window. A molecular test is priced by negotiation, by bundle, or by whatever a health system will bear for a result that changes a treatment decision. A chemistry panel is priced from a fee schedule: a list, printed by a government, containing a number for every analyte. That single property explains why the largest discipline in diagnostics by test volume is the slowest by value growth — **5.13 per cent more results a year against 3.71 per cent more revenue, with realised revenue per reportable result falling 10.26 per cent from USD 0.780 to USD 0.700** — and why this forecast is a price forecast with a volume forecast attached, rather than the other way round.

 | Indicator |  | 2025 |  | 2033 |  | Change |

 | Market value (USD m) |  | 16,800.0 |  | 22,490.0 |  | +5,690.0 |

 | CAGR, 2025–2033 |  | 3.71% (1.339x) |

 | Reportable results (million) |  | 21,540 |  | 32,130 |  | 5.13% CAGR |

 | Realised revenue per result (USD) |  | 0.780 |  | 0.700 |  | −10.26%, −1.34% a year |

 | Share of global IVD value |  | 16.02% |  | 13.64% |  | −2.38 pp |

 | Clinical chemistry reagents, calibrators and controls |  | 9,744.0 (58.0%) |  | 12,730.0 (56.6%) |  | 3.40% CAGR |

 | Urinalysis reagent strips and consumables |  | 2,268.0 (13.5%) |  | 2,564.0 (11.4%) |  | 1.55% CAGR |

 | Attributed to six disclosed pools |  | 8,207.0 (48.9%) |  | Stated residual 8,593.0 (51.1%) |

## The only discipline whose price is a document rather than a negotiation

Most of in vitro diagnostics is priced by a market. This part of it is priced by a formula and an award notice, and the difference matters because a formula arrives on a date.

Three mechanisms set the price of a chemistry test, in order of force. **Published fee schedules** determine what a laboratory is paid, and therefore what it can afford to pay a vendor plus its own cost of running the test; in the United States that is the Clinical Laboratory Fee Schedule, and in China it is the provincial test price, of which the Beijing public hospital price is the reference ceiling. **Public tender** discovers the price competitively and immediately, because a procurement alliance awards volume against that ceiling in a single round. **Private contracting** erodes it slowly, laboratory by laboratory, in the markets that have neither. Nothing in that chain has become more favourable. The two mechanisms that set the most revenue both moved down inside the forecast window, and neither move was caused by a fall in demand.

There is a second-order point that carries more weight than the size of either cut. A cap defers a reduction; it does not forgive one. The American schedule converts what would have been a single adjustment into a three-year staircase, which means the effect arrives later and the uncertainty about 2030 arrives instead.

## Two schedules, one window, two different shapes of cut

**The United States.** In September 2026 the Centers for Medicare & Medicaid Services published preliminary 2027 rates for the Clinical Laboratory Fee Schedule and, for the first time since 2018, applied the market-based methodology legislated in the Protecting Access to Medicare Act of 2014 rather than the historical Medicare rates. The calculated medians came in below the 2026 schedule for **1,171 codes**, above it for **186** and unchanged for **169**. By category, **chemistry was down 16 per cent across 387 codes** — a smaller reduction than molecular pathology at 22 per cent and genomic sequencing at 23 per cent, and far larger than proprietary laboratory analysis at 2.4 per cent, but applied to the largest category on the schedule by test volume. Legislation passed with the 2026 budget established a **15 per cent cap on annual reductions for 2027 through 2029**; the American Clinical Laboratory Association counted **775 tests that would take the full 15 per cent in the first year**; and CMS projected the methodology would save Medicare **USD 1 billion annually**. The reset also propagates well beyond Medicare, because Medicaid fee-for-service payments are statutorily prohibited from exceeding the corresponding fee-schedule rate and commercial plans generally use the schedule as a contracting baseline.

**China.** The same mechanism has already run there, with the price controlled from the other end. Provincial procurement alliances set price by awarding volume against a published ceiling, and biochemical specifications are where the format was perfected. The Jiangxi alliance awarded **2,314 specifications at an average price cut of roughly 70 per cent**. Abbott states the consequence in its own results commentary, without naming a country’s policy: Core Laboratory growth “in other geographies was partially offset by challenging market conditions in China, including the impact of volume-based procurement programs.”

Set the two numbers beside each other and the shapes are not comparable, which is the point. **Sixteen per cent a year for three years is a staircase. Seventy per cent in a single award is a cliff.** Both are administered prices, both are inside this forecast, and together they are the entire content of the 3.71 per cent rate.

## The 2025 disclosures, and the way they sort

Six companies break out enough of their chemistry business to be measured. They did not move together, and the pattern of who moved which way is the second half of the argument.

**Roche’s core laboratory business was flat at CHF 7.6 billion** — USD 8,740 million at CHF 1.15 — **and the flatness conceals a split. Immuno-diagnostics fell 3 per cent while clinical chemistry rose 7 per cent.** Same customers, same tenders, same quarter. The Anhui alliance that reset Chinese immunoassay prices in 2024 targeted tumour markers and thyroid function specifically; chemistry had not yet been repriced at the same scale. Within one company, the discipline that had already been tendered shrank and the one that had not grew. Roche’s diagnostics sales in China fell 24 per cent for the year and took Asia-Pacific down 12 per cent while every other region grew at a mid-single-to-low-double-digit rate.

**Abbott’s Core Laboratory revenue was USD 5,360 million, up 2.1 per cent organically**, with the United States at **USD 1,425 million and up 7.0 per cent** and international at **USD 3,935 million and up 0.4 per cent**. The United States is 26.59 per cent of that business and grew seventeen times faster than the rest of it. Abbott’s total diagnostics franchise fell 4.5 per cent organically, but excluding COVID-19 testing-related sales — which fell from USD 747 million to USD 297 million — it grew 0.4 per cent. **Core Laboratory was the only division inside diagnostics that grew at all.**

**QuidelOrtho’s Labs segment — the Vitros franchise, overwhelmingly North American chemistry and immunoassay — was USD 1,505.7 million, up 5.7 per cent at constant currency**, against a total company down 2.1 per cent on the same basis. The chemistry business grew while the company shrank. **Siemens Healthineers** closed fiscal 2025 with Diagnostics comparable revenue at *minus* 0.3 per cent in the fourth quarter and an adjusted EBIT margin of **7.5 per cent**, the lowest of the group’s four segments and the one most exposed to tendered chemistry. **Danaher’s Diagnostics segment** grew 1.5 per cent on a core basis at an operating margin of **26.7 per cent**, the highest in the set and the one carrying the least tendered chemistry per dollar of revenue.

Then the two Chinese vendors, which is where the deflation actually lands.

**Mindray’s in vitro diagnostics segment was RMB 12,241 million, down 9.41 per cent**, and remained the company’s largest product line at **36.78 per cent of group revenue**. Domestic revenue fell 22.97 per cent while international grew 7.40 per cent. The group fell 9.38 per cent to RMB 33,282 million and net profit fell 28.01 per cent. **Dirui Industrial — the closest thing to a pure-play urinalysis and clinical chemistry vendor listed anywhere — reported revenue of RMB 807.06 million, down 17.41 per cent**, and swung from an adjusted profit of RMB 65.16 million to a net loss of RMB 245.99 million. Its auditor issued a qualified opinion on the accounts and an adverse opinion on internal control. Operating cash flow collapsed 113 per cent to RMB 38.8 million, and the company booked large asset impairments against a domestic book built on instrument placements.

Put those six rows in one column and the sorting is unambiguous. **The vendors selling commoditised chemistry into a tendered domestic market lost a fifth of their revenue. The vendors selling differentiated chemistry into a fee-for-service market grew at a low single digit.** The discipline did not fail. It was repriced, and the repricing found the least defensible product first.

## 48.9 per cent attributes and 51.1 per cent does not — and that is the finding, not a gap

Of the USD 16,800 million base, only **USD 8,207 million — 48.9 per cent — can be attributed to companies that disclose enough to be measured**. The remaining **USD 8,593 million** is unlisted domestic supply: Chinese, Indian, Japanese, Korean, Brazilian and Turkish reagent manufacturers, most of which sell into their home market only and none of which break out chemistry revenue.

 | Disclosed pool |  | Reported pool revenue, 2025 |  | Estimated chemistry and urinalysis share |  | Attributed (USD m) |  | Share of attributed pool |

 | Roche Diagnostics — core laboratory (CHF 7,600m) |  | USD 8,740m |  | 30.0% |  | 2,622 |  | 31.9% |

 | Abbott — Core Laboratory |  | USD 5,360m |  | 45.0% |  | 2,412 |  | 29.4% |

 | Siemens Healthineers — Diagnostics (EUR 4,347m) |  | USD 4,912m |  | 35.0% |  | 1,719 |  | 20.9% |

 | QuidelOrtho — Labs segment |  | USD 1,506m |  | 50.0% |  | 753 |  | 9.2% |

 | Mindray — in vitro diagnostics (RMB 12,241m) |  | USD 1,700m |  | 35.0% |  | 595 |  | 7.2% |

 | Dirui Industrial — group revenue (RMB 807m) |  | USD 112m |  | 95.0% |  | 106 |  | 1.3% |

 | **Attributed total** |  | **USD 22,330m** |  | — |  | **8,207 (48.9%)** |  | **100%** |

The pool revenues are disclosed figures. **The weights are analytical estimates**, derived from each company’s disclosed product-line commentary and menu structure and rounded to the nearest five points; they are not disclosed, and they are the least certain input in the construction. The residual is stated rather than absorbed, because at 51.1 per cent it is too large to hide inside a rounding term.

This is the lowest attribution coverage of any discipline in the cluster, and it is not a gap in the research. It is the structure of the product. **A reagent built from enzymes, substrates, buffers, a stabiliser and a calibrator can be manufactured almost anywhere**; it does not require a global distribution network or a decade of clinical evidence. When Jiangxi awarded 2,314 specifications, it could do so because there were enough qualified bidders to fill them. **Concentration and price are the same variable here, read from two ends.** Roche’s attributed position is USD 2,622 million — 15.6 per cent of the whole market — and no vendor in this discipline holds more than that.

## The analyser is given away and the reagent pays for it

A chemistry analyser is a seven-to-ten-year asset sold at or below cost, often consigned as an asset that stays on the vendor’s own balance sheet; the reagent contract that follows runs five years and is the revenue. Mindray shows the strategy in its purest form: **more than 360 new orders for its MT 8000 total laboratory automation line in China in 2025, roughly 270 installed, and its laboratory solution installed at close to 1,100 hospitals of which about 80 per cent are tertiary — in a year when its domestic revenue fell 22.97 per cent**. Placements are being bought with price because a placement is a claim on five years of reagents.

That is the mechanism behind the 5.13-against-3.71 gap. Revenue per result falls while result volume rises because **the vendors are paying to be inside the laboratory**. It is also why the balance-sheet risk sits where it does: consigned instruments are working capital in someone else’s building, and when volumes fall short of the assumption that justified the placement, the impairment lands at once. Dirui’s swing from an adjusted profit of RMB 65.16 million to a net loss of RMB 245.99 million is that mechanism arriving in full.

The margin consequence is the most revealing number in the disclosure set, and it is a spread rather than a level.

 | Company |  | Disclosed margin, 2025 |  | Measure |  | What else sits on the platform |

 | Danaher — Diagnostics |  | 26.7% |  | Operating margin, GAAP |  | Cepheid molecular, plus Beckman Coulter chemistry and immunoassay |

 | QuidelOrtho — group |  | 21.9% |  | Adjusted EBITDA margin |  | Vitros chemistry and immunoassay with a North American installed base, plus immunohematology |

 | Sysmex — group |  | 10.4% |  | Operating margin, IFRS |  | Haematology and urinalysis, almost no molecular |

 | Siemens Healthineers — Diagnostics |  | 7.5% |  | Adjusted EBIT margin, Q4 FY2025 |  | Chemistry, immunoassay, automation — heavily tendered in Europe and China |

**Those four figures are not the same measure** — operating margin, adjusted EBITDA margin and adjusted EBIT margin differ in what they exclude — so the spread should be read as directional rather than as a like-for-like ranking. The direction is not ambiguous. Siemens Healthineers Diagnostics, which sells chemistry and immunoassay into tendered European and Chinese laboratories and little else, earned 7.5 per cent. Danaher Diagnostics, which carries a molecular franchise inside the same segment, earned 26.7 per cent. And Sysmex — the global leader in urinalysis and haematology, and the most exposed to the strip and analyser economics described here — saw sales fall 1.7 per cent to JPY 500,006 million while operating profit fell 40.8 per cent to JPY 51,831 million and margin dropped from 17.2 to 10.4 per cent. A 1.7 per cent revenue decline does not produce a 40.8 per cent profit decline through volume.

So nobody can raise the price of a chemistry test, because the price is published and there is a domestic supplier willing to undercut it. Margin is defended in two ways that have nothing to do with assay quality: **put something else on the platform, or take cost out of the placement.**

## The only blocks growing faster than the market are the ones no fee schedule prices

 | Product block |  | 2025 (USD m) |  | Share |  | 2033 (USD m) |  | Share |  | CAGR |

 | Clinical chemistry reagents, calibrators and controls |  | 9,744 |  | 58.0% |  | 12,730 |  | 56.6% |  | 3.40% |

 | Clinical chemistry analysers and instruments |  | 2,856 |  | 17.0% |  | 4,048 |  | 18.0% |  | 4.46% |

 | Urinalysis reagent strips and consumables |  | 2,268 |  | 13.5% |  | 2,564 |  | 11.4% |  | 1.55% |

 | Automated urine sediment and microscopy analysers |  | 840 |  | 5.0% |  | 1,372 |  | 6.1% |  | 6.32% |

 | Service, laboratory automation and data |  | 1,092 |  | 6.5% |  | 1,776 |  | 7.9% |  | 6.27% |

 | **Total** |  | **16,800** |  | **100%** |  | **22,490** |  | **100%** |  | **3.71%** |

Reagent share falls, from 58.0 to 56.6 per cent, because **instrumentation is being given away to capture it**: instruments grow at 4.46 per cent against reagents at 3.40. The instrument is not becoming a better business. It is becoming a more expensive entry ticket.

The two fastest blocks are automated urine sediment at 6.32 per cent and service, automation and data at 6.27, and **neither is priced by a fee schedule** — one is an instrument, the other is a service line. Service rising from 6.5 to 7.9 per cent of the market makes it the only line in the whole structure with no published price against it, which is also why a laboratory staffing shortage is an upside risk in this report rather than a cost. Total laboratory automation is the real capital cycle here: sample sorters, decappers, centrifuges, aliquotters, conveyors and middleware, sold on labour rather than assay performance, and the strongest lock-in mechanism in diagnostics — once a laboratory’s sample flow is built around a track, replacing the analysers attached to it becomes a re-engineering project rather than a procurement decision. Mindray’s 360-plus orders in a year of falling domestic revenue is a company buying exactly that.

At the bottom of the table sits the block the market is quietly exiting. **Reagent strips grow at 1.55 per cent, the slowest line in the forecast**, because a dipstick is a qualitative panel with a fixed number of pads, a fixed price and no menu to trade up into.

## Urinalysis is being replaced rather than repriced

That distinction is the boundary decision that keeps urinalysis inside a chemistry report rather than in one of its own, and it runs in two steps.

First, **automated sediment analysis took the microscopy labour out of the test**. Flow cytometry classifies particles by scatter and fluorescence as they pass a detector; digital imaging photographs the sediment in a counting chamber and classifies formed elements algorithmically. Both removed the technologist’s eye from the loop and moved the test from a labour cost to an instrument cost. Then **the clinical question left too**. Automated microscopy made the dipstick cheaper to abandon without making it more valuable. What made the urinary test valuable again was quantification.

**The KDIGO 2024 guideline for the evaluation and management of chronic kidney disease stages the disease on albuminuria categories as well as GFR categories.** That converts urine albumin-to-creatinine ratio from an optional dipstick reflex into a recurring, quantitative, guideline-mandated order, and the assay that answers it is immunoturbidimetric, run on a chemistry analyser, bought by a chemistry buyer. Diabetes and hypertension prevalence then do the volume work. **Value migrates from the strip to the analyser, and out of urinalysis into chemistry, without the patient population changing at all.** Urine chemistries are 11.0 per cent of this market in 2025 and the fastest-growing analyte class inside it, while strips fall from 13.5 to 11.4 per cent of value and sediment analysers rise from 5.0 to 6.1.

## The open channel is the residual, and the residual is the price

A closed chemistry platform accepts only the manufacturer’s own reagents. An open-channel platform accepts user-defined parameters: the laboratory, or a third-party reagent maker, sets the wavelength, the volumes, the incubation time and the calibration model, and runs its own chemistry on the instrument. The Beckman Coulter AU family is the archetype, and its installed base is the reason an entire segment of this industry exists — manufacturers across China, India and Europe publish AU-compatible applications for their chemistry kits and sell into laboratories that already own the analyser.

**Every open platform in the field is a permanent invitation to the 51.1 per cent.** Which is why vendors have spent a decade moving toward closed, integrated, automation-linked systems: not because the chemistry is better on them, but because closing the channel is the only way to protect reagent price once the fee schedule has fixed revenue per test. The same logic runs through regulation. ISO 17511 and the Joint Committee for Traceability in Laboratory Medicine standardise results, and standardised results are interchangeable results — so every standardisation event, from creatinine to HbA1c to cystatin C as a race-free estimate of glomerular filtration rate, converts differentiation into commodity, expanding volume while compressing price.

## Three cases, and the one event that would change the shape

If the US reset binds at the 15 per cent cap for all three years and China extends biochemical procurement to five more provinces, the market reaches **USD 20,880 million and 2.75 per cent**. On the published base case it reaches **USD 22,490 million and 3.71**. If quantitative urinary chemistry and panel expansion push volume growth toward 6 per cent, it reaches **USD 24,320 million and 4.73**. That is a band of 198 basis points, and its narrowness is the point: **the forecast is sensitive to whether two governments keep cutting administered prices, and to nothing else at comparable magnitude.**

Neither case assumes demand falls. In eight years of forecast the market never shrinks in any scenario — it simply grows more slowly than the cost of the technology that serves it. That is structural deflation in its benign form. What would change the shape rather than the number is whether the 2027 reset survives the 2028 rulemaking cycle without congressional relief: this is the first broad application of the market-based methodology since 2018, and the last one did not survive intact. Three dates matter more than any product launch — the final 2027 rates, due in November 2026; the 2028 rulemaking, which is when relief would have to appear; and the next provincial round in China.

## Scope, method and what is deliberately outside

Inside the perimeter: clinical chemistry reagents, calibrators and controls; chemistry analysers and the service contracts attached to them; blood gas and electrolyte measurement where it is performed and bought as chemistry; urine reagent strips and their readers; automated urine sediment and microscopy analysers; and the total laboratory automation that moves samples between them. Outside: immunoassay and chemiluminescence, which sit in the companion report and would double-count the shared analysers; molecular diagnostics; haematology and coagulation; point-of-care chemistry sold as a device rather than a laboratory service; and histopathology and cytology.

One boundary needed a decision. Immunoturbidimetric specific-protein assays — albumin, CRP, HbA1c, cystatin C — run on chemistry analysers and are bought by chemistry buyers, and they are in. Troponin and natriuretic peptides also run on some chemistry platforms but are bought as cardiac panels and priced as immunoassay, and they are out. Urine albumin, the test that sits exactly on the line, is counted in chemistry, because that is where the revenue is booked and where the growth is. On that perimeter the level is 16.02 per cent of the USD 104.9 billion diagnostics base used across this cluster; adding immunoassay’s USD 26,400 million gives **USD 43,200 million, or 41.2 per cent** of that base — the routine core of the laboratory, and the block everything else in diagnostics is built on top of.

The method is a deliberate 70/30 split between secondary and primary evidence. The secondary layer is the disclosed record: annual reports and results releases from Roche, Abbott, Siemens Healthineers, Danaher, QuidelOrtho, Sysmex, Mindray and Dirui Industrial; the preliminary 2027 Clinical Laboratory Fee Schedule and the PAMA reporting cycle; provincial procurement award notices from China; the KDIGO 2024 guideline; and FDA clearance records. The primary layer is 41 depth interviews across 11 markets, 26 open-ended interviews specifically on how a chemistry tender is sequenced and how a fee-schedule code is set, a 164-respondent structured survey, and observation at four industry conferences — used to explain mechanism only, never to carry a number. **No published aggregate was used to set the level:** the base is built bottom-up from six disclosed pools, each weighted by an estimated chemistry-and-urinalysis share, plus a stated residual. Volume is a modelled derivative of revenue divided by an implied realised price per reportable result, and is directional rather than measured; the USD 0.780 and USD 0.700 unit figures are nobody’s disclosure. Currency translation uses 2025 average rates throughout: EUR 1.00 = USD 1.13, CHF 1.00 = USD 1.15, JPY 148 = USD 1.00, CNY 7.20 = USD 1.00.

## Related research in this cluster

[Global In Vitro Diagnostics Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-in-vitro-diagnostics-ivd-market/) — the head report, USD 104.9 billion in 2025 to USD 164.9 billion in 2033 at 5.82 per cent. [Global Immunoassay Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-immunoassay-market/) — USD 26,400 million at 4.90 per cent, the other half of the routine core and the same tender mechanism arriving a year earlier. [Global Haematology and Coagulation Diagnostics Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-haematology-and-coagulation-diagnostics-market/) — USD 7,620 million at 4.25 per cent, which reads the same 2027 schedule from the other side. [Global Microbiology Diagnostics Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-microbiology-diagnostics-market/) — the other discipline priced by the same statute, where 224 codes were cut 19.3 per cent. [Global IVD Reagents and Consumables Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-ivd-reagents-and-consumables-market/) — which places this discipline’s consumable content inside the wider layer, where chemistry reagents are 15.00 per cent of it and the slowest-growing of nine product classes at 3.00 per cent. [Global Clinical Laboratory Services Market, 2026–2033](https://www.pheonixresearch.com/healthcare/healthcare-services/market-report/global-clinical-laboratory-services-market/) — the buyer, whose economics turn on the 2027 reset described above.

## Companion analysis

Three articles read this report’s evidence from different ends. [The First Broad Reset Since 2018 Cuts Chemistry Sixteen Per Cent](https://www.pheonixresearch.com/healthcare/diagnostics/article/the-first-broad-reset-since-2018-cuts-chemistry-sixteen-per-cent/) takes the 2027 fee schedule apart — 387 chemistry codes, 775 tests at the cap in year one — and sets it beside the Jiangxi award that moved the same price by 70 per cent in a single act. [Sysmex Took 1.7 Per Cent Off Sales and 40.8 Per Cent Off Operating Profit](https://www.pheonixresearch.com/healthcare/diagnostics/article/sysmex-took-1-7-per-cent-off-sales-and-40-8-per-cent-off-operating-profit/) is the margin consequence: an analyser is a fixed commitment and the reagent is the annuity that pays for it. [KDIGO Turned a Dipstick Into a Chemistry Assay](https://www.pheonixresearch.com/healthcare/diagnostics/article/kdigo-turned-a-dipstick-into-a-chemistry-assay/) is the one place in this discipline where volume and price can rise together, and it is why urinalysis sits inside a chemistry report rather than in one of its own.

## About this report

*Global Clinical Chemistry and Urinalysis Market Report, Size, Share and Forecast 2026-2033: More Results, Less Money Each* is 16,800 million US dollars of 2025 market value built from six disclosed corporate pools and a stated residual, with three scenario paths, a full product, end-market, regional and analyte-class segmentation, and a value-chain and margin analysis of where rent accrues in a discipline with a chokepoint at both ends and none in the middle. It is one of six discipline and layer reports that reconcile to a single USD 104.9 billion in vitro diagnostics base.

## About Pheonix Research

Pheonix Research produces market intelligence for decisions that turn on price, volume and structure rather than on narrative. Its method is to build a market from disclosed pools upward, state the residual rather than absorb it, and put a number on the mechanism that sets the price — here, two fee schedules and one award notice.
